Current Status of the Diagnosis of Early-Stage Pancreatic Ductal Adenocarcinoma.
Kazunori NakaokaEizaburo OhnoNaoto KawabeTeiji KuzuyaKohei FunasakaYoshihito NakagawaMitsuo NagasakaTakuya IshikawaAyako WatanabeTakumi TochioRyoji MiyaharaTomoyuki ShibataHiroki KawashimaSenju HashimotoYoshiki HirookaPublished in: Diagnostics (Basel, Switzerland) (2023)
Pancreatic ductal adenocarcinoma (PDAC) can be treated with surgery, chemotherapy, and radiotherapy. Despite medical progress in each field in recent years, it is still insufficient for managing PDAC, and at present, the only curative treatment is surgery. A typical pancreatic cancer is relatively easy to diagnose with imaging. However, it is often not recommended for surgical treatment at the time of diagnosis due to metastatic spread beyond the pancreas. Even if it is operable, it often recurs during postoperative follow-up. In the case of PDAC with a diameter of 10 mm or less, the 5-year survival rate is as good as 80% or more, and the best index for curative treatment is tumor size. The early detection of pancreatic cancer with a diameter of less than 10 mm or carcinoma in situ is critical. Here, we provide an overview of the current status of diagnostic imaging features and genetic tests for the accurate diagnosis of early-stage PDAC.
Keyphrases
- early stage
- current status
- high resolution
- minimally invasive
- coronary artery bypass
- small cell lung cancer
- squamous cell carcinoma
- healthcare
- patients undergoing
- sentinel lymph node
- prognostic factors
- mass spectrometry
- radiation induced
- fluorescence imaging
- acute coronary syndrome
- percutaneous coronary intervention
- chemotherapy induced